A vaccine for triple-negative breast cancer that is still present after chemotherapy
Part of Cancer, Skin clinical trials.
This study tests a vaccine called STEMVAC for people with triple-negative breast cancer who still have some cancer left after chemotherapy and surgery. The vaccine is given after standard treatments to help your immune system attack any remaining breast cancer cells and reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer.
- You finished chemotherapy before surgery, and after surgery, some cancer remained in the removed tissue (called residual cancer burden, or RCB).
- You are planning to receive standard treatments like radiation or hormone therapy after surgery.
- You are not planning to take the drug olaparib (a type of targeted therapy) during the study.
- You have not had a major heart condition or an autoimmune disease requiring treatment.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.